Massachusetts Institute of Technology
Sign in

What Can We Learn From Related Industries?

08/12/2004 3:15PM Wong Auditorium
Scott Sarazen, Senior Vice President, Life Sciences, MassDevelopment; Andrew Parece, Vice President, Analysis Group/Economics Analysis Group, Inc; Tamsin S. Randlett, Senior Director, Government Affairs, Gap Inc. ; Stephen M. Sammut, Venture Partner, Burrill & Company

Description: In some ways, the pharmaceutical industry is unique from other industries, its upfront R&D costs, for instance are extremely high. But these panelists see some commonalities with other business sectors, and offer observations and counsel to drug manufacturers. Andrew Parece focuses on the trade of high tech goods, such as software, digital cameras and DVDs. There are difficulties controlling the free flow of these goods, and their prices, across borders a challenge the drug industry also confronts today. Parece suggests that pharma companies "leverage their competitive advantage 'to differentiate products, and turn offerings into products and services such as patient assistance and education, and disease management." Tamsin Randlett of Gap, Inc. deals more with issues on the manufacturing end. The Gap outsources clothing production to companies in parts of the world where wage and labor standards lag. To respond to concerns about equity and human rights, Randlett partners with international labor organizations and NGOs. She suggests pharmaceutical industries similarly "leverage world health organizations 'to bring greater credibility to your efforts" and sit down with politicians, even those opposed to industry positions. Stephen Sammut's venture capital group invests in the biosecurity business. Just as in drug manufacturing, biosecurity involves risky and expensive R&D, licensing and liability questions, and unpredictable market size. Since "northern hemisphere concerns about biosecurity are the daily disease burden of many countries in the southern hemisphere," says Sammut, one answer to the pricing problem may be creating drugs useful for both markets simultaneously.

Host(s): Sloan School of Management, MIT Sloan School of Management

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments.

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated 6 months ago

Created
December 13, 2011 11:18
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
3129 times

More from MIT World — special events and lectures

Why Bad Things Happen to Good Technologies

Why Bad Things Happen to Good Techn...

Added over 4 years ago | 00:55:08 | 2609 views

Electrons, Life and the Evolution of the Oxygen Cycle on Earth

Electrons, Life and the Evolution o...

Added over 4 years ago | 00:53:51 | 3143 views

America's Leadership in Clean Energy

America's Leadership in Clean Energy

Added over 4 years ago | 00:28:38 | 10357 views

Weapons of Mass Confusion: Assessing the True Risks

Weapons of Mass Confusion: Assessin...

Added over 4 years ago | 02:01:00 | 2994 views

Reflections on the Big Dig

Reflections on the Big Dig

Added over 4 years ago | 00:46:10 | 3167 views

Handel As Orpheus: Voice and Desire in the Chamber Cantatas

Handel As Orpheus: Voice and Desire...

Added over 4 years ago | 01:11:00 | 4164 views